This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Good day and thank you for standing by. Welcome to the Inside Group, Inc. Q1 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today. Mr. Keech, please go ahead.
spk06: Thank you, Gigi, and welcome, everyone. We filed our earnings press release yesterday, and it is available on the investor relations section of our website at theenzymegroup.net. A replay of this call will also be available on our website at 5 p.m. Pacific on Friday, May 26, 2023. We want to remind any listeners that may be listening to a replay of this call that all statements made are as of today, April 27, 2023, and these statements have not been nor will be updated subsequent to today's call. Also, any forward-looking statements made today are based on management's current expectations, assumptions, and beliefs about our business and the environment in which we operate. These statements are subject to risks and uncertainties that could cause our actual results to materially differ from those expressed or applied on today's call. Listeners should not place undue reliance on forward-looking statements and are encouraged to review our SEC filings for a more complete discussion of factors that could impact our results. Except as required by federal securities laws, Ensign and its affiliates do not undertake to publicly update or revise any forward-looking statements where changes arise as a result of new information, future events, changing circumstances, or for any other reason. In addition, the Enzyme Group, Inc. is a holding company with no direct operating assets, employees, or revenues. Certain of our wholly owned independent subsidiaries, collectively referred to as the service center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to the other operating subsidiaries through contractual relationships with such subsidiaries. In addition, Our wholly-owned captive insurance subsidiary, which we refer to as the insurance captive, provides certain claims-made coverage to our operating companies for general and professional liability, as well as for workers' compensation insurance liabilities. Ensign also owns Standard Bear Healthcare REIT, Inc., which is a captive real estate investment trust that invests in healthcare properties and enters into lease arrangements with certain independent subsidiaries of Ensign, as well as third-party tenants that are unaffiliated with the Ensign Group. The words Enzyme, Company, We, Our, and Us refer to the Enzyme Group, Inc., and its consolidated subsidiaries. All of our operating subsidiaries, the Service Center, Standard Bear Healthcare REIT, Inc., and the Insurance Captive are operated by separate, wholly-owned, independent companies that have their own management, employees, and assets. References herein to the consolidated company and its assets and activities, as well as the use of terms We, Us, Our, and similar words we may use today, are not meant to imply nor should it be construed as meaning that the Enzyme Group Inc. has direct operating assets, employees, or revenue, or that any of the subsidiaries are operated by the Enzyme Group. Also, we supplement our GAAP reporting with non-GAAP metrics. When viewed together with our GAAP results, we believe that these measures can provide a more complete understanding of our business, but they should not be relied upon to the exclusion of GAAP reports. A GAAP to non-GAAP reconciliation is available in yesterday's press release and is available in our form 10-Q. And with that, I'll turn the call over to Barry Port, our CEO. Barry?
spk07: Thanks, Chad, and thank you, everyone, for joining us today. Our local leaders and their teams continue to be examples of excellence in healthcare services as they navigate through constant changes in each of their markets. Yet again, our locally driven strategy led to continued improvement in occupancies, skilled revenue, and skilled census. We were particularly pleased that we achieved sequential growth in overall occupancy for the ninth consecutive quarter, with same store and transitioning operations increasing by 4.2 and 5.4% respectively over the prior year quarter. As of the end of the quarter, our same store occupancy reached 78.8%, and we continue to get closer to our pre-COVID occupancy level which was at 80.1% in March of 2020. The record results our leaders achieved this quarter are particularly impressive given the ongoing disruption in the labor market. Although we still have headwinds from these labor market challenges, our turnover is improving significantly year over year over year, and our utilization of agency labor is trending down for the fourth month in a row. We also continue to build stronger relationships with our managed care partners due to better coordination of care, increased clinical capabilities, and strong clinical outcomes. As a result, during the quarter, our same store operations grew skilled mix revenue and skilled mix days by 5.4% and 3.5%, respectively, over the prior year quarter. In addition, we saw increased volume in our same store managed care census and managed care revenue. which increased during the quarter by 9% and 11.9% respectively. As we evaluate our expanding portfolio, we see more organic growth potential within our existing operations than ever before. As we relentlessly follow and protect the cultural fundamentals that got us here, we are confident that we will continue to consistently achieve outstanding clinical and financial performance. As we indicated last quarter, we continue to see that our skilled NICs for both revenue and census remains elevated when compared to pre-COVID levels, showing just how important high-quality post-acute services are within the continuum of care. We are pleased to see this continuous growth in skilled NICs as it demonstrates the increasing and sustainable demand for skilled post-acute services. Throughout our history, we've demonstrated the ability to find, transition, and improve our newly acquired operations. This ability, combined with a strong balance sheet, allows us to increase the number of acquisitions we close in times of market turmoil, when many operators are either choosing or being forced to exit the industry. Most of the operations we acquire are struggling clinically and financially at the time we acquire them, and they can often take many quarters to become a facility of choice in their community and it contributes to the organization's results. In some cases, however, if the foundation for solid clinical performance is in place at the time of acquisition, the performance can sometimes happen more quickly. During the quarter, we transitioned 17 California operations that were previously operated by North American Healthcare. When we announced the deal that last year, we indicated that we were going to inherit operations that, for the most part, came to us with a strong clinical reputation. an outstanding team of clinical leaders. We also noted that like most of our recent deals, we expected some challenges related to higher than normal agency staffing prior to the acquisition, as well as some additional opportunities on the expense management front. We are pleased to report that with just two months of operations under our belts, this large acquisition is performing ahead of schedule and is already contributing to our results. While these operations will face some continued challenges during the year, including some potential pressures on occupancy that are typical during summer months, we are really excited to have the opportunity to work together with our new partners to drive more efficiency. We look forward to the contribution they will continue to make to this organization over the next 20 to 30 years. In our new business ventures, we've seen greater improvement and better momentum. This entrepreneurial incubator program is one of the elements of our culture that helps us attract and retain outstanding leaders, which allows our proven leaders to explore new post-acute care businesses and gives Ensign great investment opportunities, all while keeping the opportunities within the Ensign family. While currently these new ventures collectively represent a very small percentage of our overall business, as we've shown in the past with our home health and hospice business, These opportunities have the potential to become significant. Due to our solid skilled mix and very strong sequential occupancy growth, as well as stronger than expected results from our recent acquisitions, we are increasing our annual 2023 earnings guidance to between $4.64 and $4.77 per diluted share, up from $4.60 to $4.74 per diluted share. This new midpoint of our 2023 earnings guidance represents an increase of 14% over our 2022 results and is 29% higher than our 2021 results. We are also raising our annual revenue guidance to between 3.68 billion and 3.73 billion, up from our previous guidance of 3.55 billion to 3.62 billion. We are excited about the upcoming year and confident that our partners will continue to manage and innovate through all the lingering challenges on the labor front. Our organization is extremely healthy, and our local operations and clinical leadership has never been stronger. Our culture and local approach that we've practiced since 1999 gives us confidence that we can and will continue to innovate and grow. While market dynamics can lead to some near-term quarterly fluctuations we remind you that our model is built for times like these. We have seen and fully expect to see that continue throughout 2023 and beyond. Next, I'll ask Chad to add some additional insights regarding our recent growth. Chad?
spk06: Thank you, Barry. During the quarter, the company added 17 skilled nursing operations in California, adding 1,462 operational breads to the portfolio, and two skilled nursing operations in Colorado. adding an additional 302 new operational beds. As we evaluate growth over the last 12 months, we can see that our discipline is paying off as we have added 42 new operations, totaling 4,640 beds. While we have literally been presented with several hundred opportunities over the last 12 to 18 months, we remain patient and we're careful to stick to our fundamental growth principles and are pleased to see most of these operations already contributing to the bottom line. We remain confident that our operating model will continue to allow local leaders to form their own market-specific strategies and to adjust to the needs of their medical communities, including methods for attracting new healthcare professionals into our workforce while retaining and developing existing staff. We continue to expect all our transitions to take time, particularly given the current labor markets, but with each acquisition, we are creating new opportunities for the next generation of leaders I look forward to working together to help each operation reach its enormous clinical and financial potential. We continue to see a wide range of large, medium-sized, and small portfolios and have recently seen the pace of these new opportunities picking up over the last few months. We always place the highest priority on growth opportunities within our existing footprint and are very excited about the additions to some of our most mature markets. including Arizona, Washington, Texas, and Colorado. As we carefully select acquisition targets, we prioritize those that give us exposure to new markets and states we already operate in, or that enhance our service offerings in markets we've been in for years. We continue to look at new states as well, but as we've said before, entering new states is challenging and can often take time to gain the trust of the local healthcare community. With the success that we continue to enjoy in South Carolina, we hope that we will be able to continue to build the Enzyme footprint in nearby southern states. Our real estate investment trust, Standard Bearer, is now comprised of 103 owned assets, which are leased to 75 affiliated skilled nursing and senior living operations, and 29 senior living operations that are leased to the Pennant Group, Inc. Each of these properties is subject to triple net long-term leases and generated rental revenue of $19.7 million for the quarter, of which $15.9 million was derived from Enzyme-affiliated operations. Also for the quarter, Standard Bear produced $13.2 million in FFO, and as of the end of the quarter, had an EBITDAR to rent coverage ratio of 2.5 times. Looking forward, we are prepared for even more growth in 2023. With the recent influx of new opportunities in some of our core states, we are seeing some compelling opportunities on both the operational and the real estate front in which we hope to participate if the pricing is right. With our locally driven operating model, we have lots of bandwidth to grow across dozens of markets. And with our increased credit agreement and a healthy amount of cash on hand, we have a lot of dry powder to grow. We expect some of the industry-wide changes on the horizon to lead to even more opportunities in the near and long-term future. Lastly, during the quarter, we paid a cash dividend of 5.75 cents per share. And as a reminder, in December, we increased our annual dividend for the 20th consecutive year. And given our strength, we plan to continue our 21-year history of paying dividends into the future. We also continue to delever our portfolio, achieving a lease-adjusted net debt to EBITDA ratio of 2.06 times. which is particularly impressive given the amount of growth we have taken in the last year. Currently, we have over 590 million in available capacity under our line of credit, which, when combined with the cash on our balance sheet, gives us more than 900 million in dry powder for future investments. We also own 108 assets, of which 103 are held by standard bearer, and 84 of which are owned completely debt-free. and are gaining significant value over time, which adds even more liquidity to help us with future growth. And with that, I'll turn the call over to Spencer Burton, our COO, to add more color around our operations. Spencer?
spk05: Thank you, Chad, and hello, everyone. In his opening remarks, Barry emphasized the significance of locally driven leadership and our ability to thrive in spite of the significant market challenges. I'd like to share a few facility examples that illustrate how leaders are finding ongoing success by customizing their operations to the needs and opportunities in the communities they serve. The first example comes from West Texas. The Medical Lodge of Amarillo was acquired in November of 2020 during the height of the COVID pandemic. On the transition date, this 102-bed facility had a census of just 38 residents, two of them skilled patients. And the operation was struggling mightily with clinical challenges, low staffing, and a poor reputation in the community. In spite of the challenges, our local team went to work building a culture and strengthening clinical capability. And over the past two years, its results and reputation have drastically improved. For example, staff turnover has decreased as the medical lodges become an employer of choice for post-acute professionals in Amarillo. With increased clinical talent, the facility has been able to improve census and skilled mix significantly, while also completely eliminating contract labor. The emphasis on quality is naturally driving financial results. In Q1, occupancy averaged 83%, up from 61% in Q1 of 2022. And the facility now enjoys a skilled mix of over 50%. As you'd expect, quarterly net revenue and EBIT improved drastically, up by 69% and 324%, respectively, over prior year quarter. The results are impressive. But CEO Chris Cantrell and DON Carol Tussek aren't satisfied yet. They and their team remain humble and hungry to learn and to apply new approaches to improving outcomes and results. One example of that occurred last year when Carol traveled from Amarillo to Mesa, Arizona to visit Montecito, an Ensign-affiliated facility that leads the entire organization in monthly admissions by providing high-acuity solutions to hospital and managed care partners. Carol was inspired and since that visit she and her nurse leadership team have worked relentlessly to build clinical competence and to offer unique high acuity programs at the Medical Lodge. The Amarillo healthcare community is taking note. Medicare days have increased by 78% and managed care days have grown by an incredible 120% as the facility has gained preferred provider status with multiple plans. Not only does the medical logitory illustrate the enormous upside in transitioning operations, it also demonstrates the endless opportunities for improvement that come as our operators seek for and share best practices, peer to peer, even across state lines. Speaking of best practices, our second facility example is an operation that's been affiliated with Ensign since 2004. During that time, North Mountain Medical in Phoenix, Arizona has innovated and raised the bar over and over again. During the past decade, this team has accomplished multiple deficiency-free CMS surveys and consistently maintained five-star quality and overall ratings. They've done this while caring for an ever-increasing level of acuity. Today, 100% of their patients require complex respiratory care, while many of these residents also receive bedside dialysis. The facility also has an in-house wound care team that allows them to care for and heal wounds that would normally require patients to stay in a much more expensive LTAC or acute hospital. For years, North Mountain has been one of the top performing facilities in the entire organization, as it has grown acuity, skilled mix, and added clinical capabilities that serve the community needs, while concurrently growing revenues. In spite of this, the facility continues to find ways to improve performance. It is the quintessential example of the boundless potential that exists in even the most mature same-store operations. For example, in Q1 of this year, the North Mountain team led by CEO Jeremy Bowen and COO Jackie Green grew occupancy from a respectable 81% to an incredible 96%, while also increasing skilled revenue mix to over 94%. As occupancy increased, the team concurrently focused on hiring and retention. and successfully eliminated their dependence on agency nurses. The team proactively developed innovative processes for attracting and training caregivers, and then supporting those caregivers as they gain additional skills and credentials. Despite being a very busy environment, North Mountain makes each employee feel like family, as evidenced in the facility having the lowest turnover rate among skilled nursing facilities in the Phoenix market. As North Mountain continues to achieve excellence in clinical and cultural measures, financial results invariably follow. For example, in Q1, the facility grew its total net revenue by 21% over prior year quarter, while EBIT increased by 63.9% for the same period. North Mountain continues to provide an example of excellence to the entire organization, while demonstrating the enormous potential that legacy operations have to continue to grow results. We hope that these examples are helpful in illustrating some of the many different levers our local operators are pulling in order to meet the needs of their healthcare continuum partners. With that, I'll turn the time over to Suzanne to provide more detail on the company's financial performance and our guidance, and then we'll open up for questions. Suzanne?
spk03: Thank you, Spencer, and good morning, everyone. Detailed financials for the quarter are contained in our tank queue and press release filed yesterday. Some additional highlights for the quarter include the following. Gap diluted earnings per share was $1.05, an increase of 18%. Adjusted diluted earnings per share was $1.13, an increase of 14.1%. Consolidated gap revenues and adjusted revenues were both $886.8 million, an increase of 24.3%. Gap net income was $59.9 million, an increase of 18.9%. An adjusted net income was $64.6 million, an increase of 14.6%. Other key metrics as of March 31st, 2023 include cash and cash equivalents of $327 million, cash flow from operations of $48.3 million, and $593 million of availability on a revolving line of credit. We also wanted to address the current status of the state of emergency and reimbursement matters. With the public health emergency ending on May 11, 2023, the majority of the states we operate in have adopted programs that will either increase the Medicaid rate or continue enhanced Medicaid funding throughout the end of the year, ensuring a relatively smooth transition. As Barry mentioned, we are providing updated annual earnings guidance of $4.64 to $4.77 per deleted share, and annual revenue guidance of 3.68 billion to 3.73 billion. We have evaluated multiple scenarios, and based on the strength in our performance and the positive momentum we've seen in occupancy and strong skilled mix, as well as some additional strengths in Medicaid and managed care programs, has led to the increase in our guidance. Our 2023 guidance is based on diluted weighted average common shares outstanding of approximately 57.7 million, a tax rate of 25%, the inclusion of acquisitions close to date, the inclusion of management's expectations of Medicare and Medicaid reimbursement rates net of provider tax, and with the primary exclusion coming from stock-based compensation. Additionally, other factors that could impact quarterly performance include variations in reimbursement systems, delays and changes in the state budget, seasonality and occupancy and skills mix, the influence of the general economy on census and staffing, the short-term impact of our acquisition activities, variations in insurance accruals, surges in COVID-19, and other factors. And with that, I'll turn it back over to Barry. Barry?
spk07: Thanks, Suzanne. It's always important to us that we take just a minute again to thank our incredible team members, facility leaders, field resources, clinical partners, and service center support staff. I can't emphasize enough how incredibly honored and grateful we are to work alongside them and to witness their amazing sacrifice, effort, and outcomes. Many of them have picked up extra workloads in the face of staffing challenges, rolled up their sleeves to help us transition dozens of operations in the last many months, and have made other sacrifices for the benefit of their coworkers, patients, and the organization. Their commitment in serving their communities and one another has blessed the lives of so many. It's absolutely astounding to witness and an honor to be a part of that effort. Just as we've seen in the past, we most certainly expect some challenges ahead. However, we will lean on the lessons that we have learned and will continue to build on our foundational strength. We're excited about our future and look forward to continuing to show our dedication to all those that have entrusted us with the care of their loved ones. And now we'll turn the call over to the Q&A portion. Gigi, can you please instruct the audience on the Q&A procedure?
spk02: As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Scott Fidel from Stevens.
spk01: Hi, thanks. Hey, everyone. First question, just wanted to hopefully dig in a little bit just to the Medicaid rebasing process that's underway just as the enhanced FMAFs wind down, and in particular, you know, obviously a lot of A lot of focus on taxes and how that process is going here. So it would be great to get some updated intel from you in terms of what you're hearing from taxes around, you know, the efforts to get those rates properly rebased for the wide NFF maps and for the underlying cost structure that SNFs are facing in the market.
spk07: Yeah. Texas is a little nuanced in that with kind of the stepping down of FMAP support, there's not like a cliff per se, but the new rate structure won't go into place until September. So that means there's going to be kind of a gap between where we have been and where we are headed. potentially. The caveat to that, Scott, is how we've been accounting for FMAP. We've been accounting for expense-related events. That's when we apply the FMAP funding. And so there's a natural lag that exists there between when the expense occurs and how we accrue for it, which also means there's a natural kind of reserve that exists. So It won't be a stark drop-off, but there will be a gap there where we won't have the continued revenues coming in to offset all of the expenses. So there will be a combination of cost control and kind of, again, this conservative accounting method we've been leaning on. That said, there's still some unknowns. The legislative session is still ongoing. still ongoing, and there's still discussion about some bridge funding, some potential for some additional grants. So there's a lot that we don't know about. Worst case scenario, though, there might be a bit of a gap in funding, but that said, we've accounted for that already in our projections, and so there shouldn't be any disruption in how we kind of see the outlook for the year.
spk03: Yeah, and just to be clear, in the low end of the guidance, we have the gaps period from the end of the state of emergency to, you know, when the rates that we're anticipating will happen as of September 1st. So that's kind of in the low end and the high end. We've taken, you know, some continued support in those kind of summer months and a little bit more of that support coming through. So all of that's accounted for in the guidance that we've provided, including the updated guidance.
spk01: Understood and appreciate that color on the bridge dynamics. You know, maybe just in terms of just, you know, when we ultimately get to the FY 2024 rates, just, you know, any updated sentiment that you have around sort of confidence that those rates will be rebased, you know, to the extent necessary to cover the, you know, the wind down in FMAPs on a permanent basis.
spk03: Yeah, I mean, I think some of them, and I'll start, and Barry can add color on this. I think we talked about it in staying really with the larger states. Arizona, they've already done a great job. They actually did that increase last year. They're still looking probably again this year at another nice increase is what we're starting to see from them, as well as kind of phasing out the FMAP consistent with the wind down of, you know, from the 6.2 down to the 1% through every quarter. So, That's one of our larger states. As we've been talking about California, same thing. They've kept it in place the entire year. There's a lot of discussion on California with regards to rebasing that we're optimistic about. And then, yeah, so those are the big ones in Texas we just talked about. Utah, same thing. They're looking at going through the process of how to get some additional funding in place there, and they're also doing the wind down for FMAP. So, we feel really good about where the states are positioned. And, you know, some of the smaller states, not as positioned as well, but they're also smaller states, so their impact won't be as big.
spk01: Okay. Just a follow-up question, just around margins and sort of what you're assuming over the course of the year. Obviously, you did mention you know, some of the bridge dynamics that will be playing out in the second quarter as we move to the rebased Medicaid rates that will be coming in later in the year. Clearly in the first quarter, you know, you also were incurring probably some additional expenses still around, you know, integration of the North American properties. And we did see the EBITDA margin, you know, decline year over year. Maybe if you could just walk us through, you know, any extraordinary or, you You know, for example, it looked like SG&A actually, you know, bumped up year over year. I'm assuming there may have been some, you know, acquisition-related costs in there, you know, in terms of the comp. So, any visibility into that would be helpful, too.
spk03: Absolutely. Starting kind of with the cost of services, and as we've been talking for years, obviously, when we have large acquisitions, that is going to drive that cost of services a little bit higher. And I think even more particularly in the last couple of quarters, what we've seen as those acquisitions have a higher level of agency spend, that's going to even drive that cost of services up for a period of time. And so as we continue to get those acquisitions in our base and then really get agency to be lowered quarter after quarter, we would expect that agency to go down over a period of time. And so kind of have that going to help offset maybe some of the funding gap that we have. With the SG&A, a couple of things. One is the additional cost associated with the acquisitions in Q1. But on top of that, we also have our annual meeting that bumps that up in the current quarter. So kind of all those things together make the first quarter a little bit higher than some of the other quarters that we would expect throughout the year.
spk01: Got it. And then if I could just squeeze one more in here, definitely caught the comments from Chad around still a very active pipeline and seems like there's a lot of deals still potentially to be done here. Just interested in your thinking just as, you know, clearly the industry is still waiting on the minimum staffing requirements that are expected, I guess, quote, in the spring from HHS. How does that influence your thinking on, you know, approaching deals? Is that something that you'd want to have visibility in before doing large transactions? Or would you sort of look to maybe, you know, factor in some additional conservatism just into deal pricing? Or just, you know, generally, I guess, how you're thinking about, you know, approaching deal pricing, given some of those variables that are still out there?
spk06: Yeah, great, great question. Appreciate that. And certainly have seen an uptick in opportunities just even in the last month and a half or so and excited about it. I think I'd just say, Scott, we're long-term investors. So when we're looking forward to all these growth opportunities, we're not necessarily going to underwrite to just a quarter or a year or even two years. We're looking... 5, 10, 15, even up to 30 years down the road. And so with that in mind, and certainly as we've talked about, as we acquire, we even sometimes expect that that will have a short-term drag on our earnings. That's just part of the deal. So certainly staffing and And, you know, I mean, COVID, we grew even through those challenges and are continuing to grow through that. I think what happens in terms of pricing, I mean, certainly as the supply of deals increases, that's going to have some impact on the pricing. And we've already started to see that. I think I noted in my comments just, you know, how pleased we are with the performance of the deals we've done. And a lot of that does start with the prices we pay. You know, we're always really, you know, careful to not pay for performance that we're going to create. So, and certainly, you know, I think our operator-driven acquisition program, you know, gives us an advantage because, you know, it's not Suzanne and Chad and Barry and some ivory tower that are forecasting and looking into the future. These are operators on the ground, you know, that know best what the outlook is for their markets. And so they're heavily involved in developing those pro formas that ultimately lead to the price that we're going to pay. And I think our conservative approach has served us well and will continue to serve us well. Minimum staffing requirements or whatever other change is inevitable in our industry. Frankly, those changes are what create such great opportunities for us.
spk01: Okay, great. Thanks.
spk02: Thank you. One moment for our next question. Our next question comes from the line of Ben Hendricks from RBC Capital Markets.
spk04: Hey, guys, thank you very much. I was wondering if you could talk a little bit about the agency labor exposure and the new California assets. Last quarter, you'd noted significantly higher agency in those facilities, and just wondering if there was any sequential improvement there, and then how generally you're thinking about the runway to bridging the California labor backdrop to be more in line with the legacy operations and what you described there at your Amarillo facility. Thanks.
spk07: Yeah, it's a great question. been, and I'll let Spencer chime in too if he's got anything to say, but there's certainly still, you know, a lot of wood to chop in those new acquisitions. And look, it's reflective of the overall environment, as you mentioned. I mean, we have a lot of opportunity in the state of California to improve, and the good news is we're on a path of a pretty steady improvement. I think several months in a row, at least now, in the state of California, on both a whole dollar basis and on a per patient day basis, which is really encouraging to see. But this is a challenge that we'll deal with throughout the year. It won't go away quickly. Just because of the nature of the number of workers in the space, our more strategic efforts around how to attract workers back into the space and have programs that allow us to get CNA certified and get them into our facilities. So we have efforts around that. We have efforts around how to enhance our benefits and how to have incentive programs and just our cultural principles strengthened so that we can get people excited about the space coupled with how we spend our time recognizing and rewarding our employees and sharing best practices around how to keep them engaged so that we don't lose the ones that we have. So it's not a simple answer on what we're doing about the labor backdrop, but needless to say, progress is being made and we're encouraged by it. Spencer, do you have anything to add to that?
spk05: Yeah, we have some really great clinical partners that joined us through this most recent acquisition, and that's exciting because as we give those great clinical leaders additional tools, additional abilities to really fine-tune their staffing, measure their staffing, we've really put effort into developing our data capabilities around optimizing staffing. All of those things have the effect of, hopefully, number one, improving care, and number two, you eliminate agency that's being used on staff that really isn't needed to provide great care. And so we're seeing as some of those things come to play, we're encouraged. Like Barry said, there's a lot of work to be done in these acquisitions and across the board. But I think we have ever more tools to use, and we've got a lot of energy going into it. So I'm confident we'll continue to get better.
spk03: Yeah, and I think that applies not just to the California acquisitions, but we're seeing that across the board throughout all the acquisitions that we've had. So I think that's where our hope comes.
spk04: Right. Yep. Thanks for that. And just if I could sneak one more in, you know, on the regulatory backdrop from Medicare, we have the rate proposal heading into the second year of the PDPM parity phase-in. I just wanted to get your thoughts on how you're thinking that's going to impact Enzyme specifically. And then I have to ask just what your thoughts are of what could come of the CMS minimum staffing rule. Thanks.
spk03: So on the first part, it's very consistent with what we thought. It ended up with a higher market basket increase, which is what we would expect because of the increased labor and then offsetting that, the parity adjustment. So where it ended up is very consistent with where we thought it would end up when we originally released guidance, and we're pleased and look forward to having that be part of the final rule.
spk07: On the federal staffing minimum, I would just say this, Ben. I mean, it's clear that CMS is following the directive of the White House to move forward with this. We actually expected something on this sooner. We are very involved at a national level, giving our feedback and providing some ideas pragmatic ways to discuss this or implement something like this. I imagine whatever is released in the next weeks or months will be something that's a starting point that will then go into a phase of much more discussion and Our hope is that we'll have a seat at the table with CMS and be able to try to find a solution that aligns with what the ideas are behind this and make it something that's practical and something that can be implemented reasonably. I would also imagine that there would be a long phase-in with something around a minimum of any sort There will probably be a host of exceptions and other details around that, but it's really hard to give you anything concrete around hypotheticals. We ourselves don't spend a whole lot of time on the what-ifs. We've historically been pretty good at adapting when things come out, and it's not that we're doing nothing. I just think Worrying about what we don't know yet isn't always the most productive use of our time. So long story short, we're watching it closely, we're giving feedback, and we'll see what comes out and we'll adapt accordingly.
spk04: Appreciate that commentary. Thanks again. Yeah.
spk02: Thank you. I would now like to turn the conference back over to Barry for closing remarks.
spk07: Thank you, Gigi, and we want to thank everyone for spending their time with us today and joining us on the call. Have a good day.
spk02: This concludes today's conference call. Thank you for participating. You may now disconnect.
Disclaimer